Deciphera Pharmaceuticals Inc

NASDAQ:DCPHUnited States

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

Contact Information

Headquarters

200 Smith StWALTHAM, MA, United States 02451-0099

Phone

781-209-6400

Fax

302-655-5049

Executives

Independent Chairman of the Board

Ron Squarer

President, Chief Executive Officer, Director

Steven Hoerter

Chief Financial Officer, Executive Vice President, Treasurer

Thomas Kelly

Executive Vice President, Chief Scientific Officer

Dashyant Dhanak

Executive Vice President, Chief Medical Officer

Matthew Sherman